Short Interest in Azitra, Inc. (NYSEAMERICAN:AZTR) Declines By 68.2%

Azitra, Inc. (NYSEAMERICAN:AZTR) saw a large drop in short interest during the month of May. As of May 15th, there was short interest totaling 126,538 shares, a drop of 68.2% from the April 30th total of 397,818 shares. Currently, 0.8% of the company’s shares are sold short. Based on an average daily volume of 471,811 shares, the days-to-cover ratio is currently 0.3 days.

Azitra Trading Up 12.0%

Shares of AZTR stock traded up $0.02 on Friday, reaching $0.23. 1,357,101 shares of the stock were exchanged, compared to its average volume of 474,277. Azitra has a 1-year low of $0.10 and a 1-year high of $2.40. The firm has a 50 day moving average of $0.23 and a two-hundred day moving average of $0.26.

Azitra (NYSEAMERICAN:AZTR) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.24). On average, equities research analysts expect that Azitra will post -0.25 EPS for the current year.

Azitra Company Profile

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.